CYP19A1 and breast cancer: Moreover, we recently reported a non-steroidal molecule (tamoxifen bisphenol) that also acts as a multi-target compound in ER+ breast cancer cells, since it reduces aromatase protein levels and acts as an ERα antagonist and induces ERβ up-regulation to inhibit growth and cause cancer cell death [26].